14 October 2019 | News
Fuzionaire Diagnostics partners with JAMIT
image credit- shuttershock.com
Fuzionaire Diagnostics, in partnership with Tokyo-based radiopharmaceutical company Japan Medical Isotope Technology Development K.K. (JAMIT), has announced the launch of Fuzionaire Radioisotope Technologies K.K. (FRIT).
FRIT will work to commercialize Fuzionaire Dx’s technology in Japan, expanding Fuzionaire Dx’s fluorine-18 radiolabeling platform through partnerships with Japanese pharmaceutical companies and research institutions and exploring new possibilities in alpha-emitting radiotherapeutics for cancer treatment.
The company will be led by Hiroshi Nakashita, MD, experienced in pharmaceutical industry commercial operation. Dr. Nakashita also has deep functional experience in health care policy shaping in Ministry of Health, Labour and Welfare Japan as a government official earlier in his career. Dr. Nakashita will serve as FRIT’s CEO.
Based on a breakthrough in catalysis by Chief Science Officer Anton Toutov, PhD, Fuzionaire Dx’s chemistry platform dramatically accelerates radiopharmaceutical discovery and improves manufacturing of radiolabeled molecules. This fundamentally changes the way in which researchers and clinicians are able to detect and treat disease.
Already in partnership with leading research institutes in the US, Fuzionaire Dx’s expansion to Japan represents an opportunity to leverage these capabilities in countries with a strong need for advancements in nuclear medicine.